4-{[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid | 720684-04-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid
• 英文别名: 4-[[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]methyl]benzoic acid
• CAS: 720684-04-8
• 化学式: C₂₂H₁₆F₃NO₃
• 分子量: 399.369
• InChiKey: ARNFNNOCJNCDSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-{[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid 、 (S)-2-amino-N-benzyl-2-phenylacetamide 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[(benzylcarbamoylphenyl-methyl)carbamoyl]benzylamide
  参考文献：
  名称：

  Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents

  摘要：

  We have successfully identified a number of novel MTP inhibitors with single digit nanomolar potency. Analogues 10aq and 10dq demonstrated in vivo efficacy in a murine gut retention assay. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.058
• 作为产物：
  描述：

  4-{[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid methyl ester 在 lithium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 4-{[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid
  参考文献：
  名称：

  Microsomal triglyceride transfer protein inhibitor

  摘要：

  本发明提供了具有公式(I)的微粒体甘油三酯转运蛋白（MTP）和/或载脂蛋白B（Apo B）分泌抑制剂，用于治疗肥胖及相关疾病，以及预防和治疗动脉粥样硬化和其临床后遗症，降低血清脂质，以及预防和治疗相关疾病。本发明还涉及包含本发明化合物的药物组合物，以及使用本发明化合物单独或与其他药物（包括降脂药）联合治疗肥胖、动脉粥样硬化和相关疾病/状况的方法。

  公开号：

  US20040132745A1

文献信息

• Microsomal triglyceride transfer protein inhibitor
  申请人：Pfizer Inc

  公开号：US20040132745A1

  公开（公告）日：2004-07-08

  The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other medicaments, including lipid-lowering agents. 1

  本发明提供了具有公式(I)的微粒体甘油三酯转运蛋白（MTP）和/或载脂蛋白B（Apo B）分泌抑制剂，用于治疗肥胖及相关疾病，以及预防和治疗动脉粥样硬化和其临床后遗症，降低血清脂质，以及预防和治疗相关疾病。本发明还涉及包含本发明化合物的药物组合物，以及使用本发明化合物单独或与其他药物（包括降脂药）联合治疗肥胖、动脉粥样硬化和相关疾病/状况的方法。
• MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1578725A1

  公开（公告）日：2005-09-28
• [EN] MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS<br/>[FR] INHIBITEURS DE PROTEINE MICROSOMALE DE TRANSFERT DE TRIGLYCERIDE
  申请人：PFIZER PROD INC

  公开号：WO2004056777A1

  公开（公告）日：2004-07-08

  The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other medicaments, including lipid-lowering agents.
• Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents
  作者：Jin Li、Peter Bertinato、Hengmiao Cheng、Bridget M. Cole、Brian S. Bronk、Burton H. Jaynes、Anne Hickman、Michelle L. Haven、Nicole L. Kolosko、Chris J. Barry、Tara B. Manion

  DOI：10.1016/j.bmcl.2006.02.058

  日期：2006.6

  We have successfully identified a number of novel MTP inhibitors with single digit nanomolar potency. Analogues 10aq and 10dq demonstrated in vivo efficacy in a murine gut retention assay. (c) 2006 Elsevier Ltd. All rights reserved.